JPMorgan analyst Jessica Fye downgraded Amarin to Underweight from Neutral without a price target citing headwinds in both the U.S. and Europe. The stock closed Thursday down 13% to $1.35. Amarin’s recent pricing and volume pressure in the U.S. could potentially become worse, and in Europe the company may struggle to achieve its goal of getting reimbursement and launching in multiple countries by the end of 2022 without compromising on price, Fye tells investors in a research note. Between the growing generic threat in the U.S. and what she expects to be a “slow-to-materialize” European opportunity, the analyst believes there are better opportunities for upside elsewhere in her coverage.
previous post